# US 2026/0083682 A1 · Kit for manufacture of drug-containing nanoparticles and nanoparticle composition for drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083682 A1
- Document ID: US20260083682A1
- Status: Published application
- Kind: A1
- Application number: 19/109,662
- Filed: 2023-07-26
- Published: 2026-03-26
- Earliest claimed: 2022-09-08
- Assignees: Samyang Holdings Corporation
- Applicants: Samyang Holdings Corporation
- Inventors: Go Eun Kim; Kyu Jin KYUNG; So Young KIM; Joung Pyo NAM; So Jin LEE; Jong Min PARK; Won II SEO
- Web page: https://patentgrep.com/patent/US20260083682A1

## CPC

- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 48/0041: {the non-active part being polymeric}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a kit for construction of drug-containing nanoparticles and a nanoparticle composition for drug delivery. More specifically, the present invention concerns a kit for construction of drug-containing nanoparticles and a nanoparticle composition for drug delivery, each designed to increase the efficiency of cellular drug delivery by utilizing nanoparticles that include a cationic compound and an anionic polymer compound with at least one acidic functional group.

## Claims

### Claim 1

A kit for preparing drug-containing nanoparticles, comprising:
a first chamber comprising nanoparticles comprising cationic compound and anionic polymer compound; and
a second chamber comprising drug which is effective ingredient selected from nucleic acid, polypeptide, virus or combination thereof,
wherein the anionic polymer compound has at least one acid functional group.

### Claim 2 (depends on 1)

The kit for preparing drug-containing nanoparticles of claim 1, wherein the drug-containing nanoparticles are for intracellular delivery of the drug.

### Claim 3 (depends on 1)

The kit for preparing drug-containing nanoparticles of claim 1, wherein the anionic polymer compound is anionic amphiphilic block copolymer, anionic hydrophilic polymer, anionic hydrophobic polymer, or combination thereof.

### Claim 4 (depends on 3)

The kit for preparing drug-containing nanoparticles of claim 3, wherein
the anionic amphiphilic block copolymer comprises hydrophilic block and hydrophobic block;
the anionic hydrophilic polymer comprises hydrophilic block only; and
the anionic hydrophobic polymer comprises hydrophobic block only.

### Claim 5 (depends on 4)

The kit for preparing drug-containing nanoparticles of claim 4, wherein
the hydrophilic block is one or more selected from the group consisting of polyalkylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, polyoxazoline, polyacrylamide, and derivatives thereof; and
the hydrophobic block is one or more selected from the group consisting of polyester, polyanhydride, polyamino acid, polyorthoester and polyphosphazine.

### Claim 6 (depends on 4)

The kit for preparing drug-containing nanoparticles of claim 4, wherein
the hydrophilic block is one or more selected from the group consisting of monomethoxypolyethylene glycol, monoacetoxypolyethylene glycol, polyethylene glycol, polyethyloxazoline, polymethyloxazoline, copolymer of polyethylene and propylene glycol, and polyvinylpyrrolidone; and
the hydrophobic block is one or more selected from the group consisting of polylactide, polyglycolide, polycaprolactone, polydioxan-2-one, copolymer of polylactide and polyglycolide, copolymer of polylactide and polydioxan-2-one, copolymer of polylactide and polycaprolactone, and a copolymer of polyglycolide and polycaprolactone.

### Claim 7 (depends on 1)

The kit for preparing drug-containing nanoparticles of claim 1, wherein the acid functional group is derived from an acid selected from the group consisting of inorganic acid, sulfonic acid, carboxylic acid and combinations thereof.

### Claim 8 (depends on 7)

The kit for preparing drug-containing nanoparticles of claim 7, wherein
the inorganic acid is selected from the group consisting of phosphoric acid, nitric acid, chromic acid, and combinations thereof;
the sulfonic acid is selected from the group consisting of methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, and combinations thereof; and
the carboxylic acid is selected from the group consisting of acetic acid, citric acid, gluconic acid, lactic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, phthalic acid, and combinations thereof.

### Claim 9 (depends on 1)

The kit for preparing drug-containing nanoparticles of claim 1, wherein one or more selected from the group consisting of the first chamber and the second chamber further comprise additional solvent.

### Claim 10 (depends on 9)

The kit for preparing drug-containing nanoparticles of claim 9, wherein the solvent is aqueous solvent, water miscible solvent, or a mixture thereof.

### Claim 11 (depends on 1)

The kit for preparing drug-containing nanoparticles of claim 1, wherein the second chamber further comprises one or more additives selected from pH adjusting agent, inorganic salt, saccharide, surfactant, chelating agent, or a combination thereof.

### Claim 12 (depends on 1)

The kit for preparing drug-containing nanoparticles of claim 1, which consists of: the drug which is effective ingredient selected from nucleic acid, polypeptide, virus or combination thereof; the cationic compound; the anionic polymer compound; solvent; and one or more additives selected from pH adjusting agent, inorganic salt, saccharide, surfactant, chelating agent, or a combination thereof.

### Claim 13 (depends on 1)

The kit for preparing drug-containing nanoparticles of claim 1, wherein the amount of the anionic polymer compound is 0.01 to 15 parts by weight, based on 1 part by weight of the cationic compound.

### Claim 14 (depends on 1)

The kit for preparing drug-containing nanoparticles of claim 1, wherein the cationic compound and the anionic polymer compound are used for the nanoparticle preparation in the form of solution filtered one or more times.

### Claim 15

A nanoparticle composition for drug delivery which is a composition for drug delivery comprising nanoparticle,
wherein the nanoparticle comprises cationic compound and anionic polymer compound,
wherein the nanoparticle does not comprise drug, and
wherein the anionic polymer compound has at least one acid functional group.

### Claim 16 (depends on 15)

The nanoparticle composition for drug delivery of claim 15, wherein the anionic polymer compound is anionic amphiphilic block copolymer, anionic hydrophilic polymer, anionic hydrophobic polymer, or combination thereof.

### Claim 17 (depends on 15)

The nanoparticle composition for drug delivery of claim 15, wherein the acid functional group is derived from an acid selected from the group consisting of inorganic acid, sulfonic acid, carboxylic acid and combinations thereof.

### Claim 18 (depends on 15)

The nanoparticle composition for drug delivery of claim 15, which consists of: the cationic compound; the anionic polymer compound; solvent; and one or more additives selected from pH adjusting agent, inorganic salt, saccharide, surfactant, chelating agent, or a combination thereof.

### Claim 19 (depends on 15)

The nanoparticle composition for drug delivery of claim 15, wherein the amount of the anionic polymer compound may be 0.01 to 15 parts by weight, based on 1 part by weight of the cationic compound.

### Claim 20 (depends on 15)

The nanoparticle composition for drug delivery of claim 15, wherein the cationic compound and the anionic polymer compound are used for the nanoparticle preparation in the form of solution filtered one or more times.
